Glypican-1 Antibody Detection for Prostate Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostate cancer diagnostic methods, such as digital rectal exams and PSA tests, suffer from low accuracy and high rates of false positives and false negatives, leading to inadequate detection and unnecessary invasive procedures.
Innovation Solution
The use of soluble glypican-1 as a biomarker in body fluids like blood, serum, and urine to detect prostate cancer, with specific antibodies like MIL-38 for measurement and detection, improving diagnostic accuracy by comparing levels against control samples or reference values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA tests are used to detect prostate cancer, then cancer detection is performed, but false positive rate increases to 67% and false negative rate occurs
Solution Approach 1:
The patent segments the diagnostic process by introducing a second independent biomarker (glypican-1) to complement PSA testing. This segmentation allows the diagnostic system to evaluate multiple markers separately and combine their results, thereby improving overall diagnostic accuracy and reducing false positives while maintaining cancer detection capability
Solution Approach 2:
The patent creates a composite diagnostic approach by combining measurements of two different biomarkers (PSA and glypican-1). This composite strategy leverages the complementary information from both markers to achieve superior diagnostic performance compared to single-marker testing, resolving the contradiction between detection sensitivity and measurement precision
2Ease of manufacture
If PSA cutoff of 4.0 ng/ml is used, then standard testing protocol is maintained, but sensitivity of 86% and specificity of only 33% are achieved
Solution Approach 1:
The patent performs preliminary action by measuring glypican-1 levels before making the final diagnostic determination. This preliminary measurement allows the system to pre-filter or pre-identify cases that may be false positives based on PSA alone, enabling more accurate subsequent diagnostic decisions while maintaining protocol simplicity
Solution Approach 2:
The patent implements feedback by using glypican-1 measurement results to inform and adjust the interpretation of PSA levels. The combined information from both markers provides feedback that refines the diagnostic accuracy, allowing the system to maintain simple cutoff thresholds while achieving improved reliability through integrated interpretation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the detection of prostate cancer with improved sensitivity and specificity, allowing for more accurate diagnosis and monitoring of treatment response, reducing false positives and negatives.
Implementation Method 1
contacting said body fluid sample with an anti-glypican-1 antibody
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards.